We have compared the expression of somatostatin receptor (sstr) subtypes with the outcome of somatostatin receptor scintigraphy and the effect of somatostatin receptor activation in patients with disseminated carcinoid tumours. Tumour tissues from nine patients with midgut carcinoids (ileal) and three patients with foregut carcinoids (gastric, thymic) were analysed using Northern blotting. Expression of somatostatin receptors was demonstrated in all tumours (12 out of 12), with all five receptor subtypes present in 9 out of 12 tumours. Somatostatin receptor scintigraphy using [1111n]DTPA-D-Phe1-octreotide visualized tumours in all patients (12 out of 12). The "'in activity concentrations in tumour tissue (T) and blood (B) were determined in three tumours 1-7 days after injection of the radionuclide. The T/B 1111n activity concentration ratios ranged between 32 and 651. Clinically, treatment with the long-acting somatostatin analogue octreotide resulted in marked symptom relief accompanied by a significant reduction in tumour markers, for example urinary-5-HIAA levels (28-71% reduction).
Binding studies and autoradiography using radiolabelled somatostatin-14 or -28, or its analogues, have shown that 80-90% of all neuroendocrine tumours of the gastrointestinal tract possess high numbers of somatostatin receptors (Reubi et al, 1987; 1990) . Activation of these receptors inhibits the secretion of tumour products and may also inhibit tumour growth (Kvols et al, 1986; Gorden et al, 1989; Wangberg et al, 1991; Saltz et al, 1993; Arnold et al, 1996) . The use of long-acting somatostatin analogues, for example octreotide, has become a well-established medical treatment strategy with excellent control of patient symptoms (Gorden et al, 1989) . Scintigraphy using [ll1n]DTPA-D-Phel-octreotide has become a valuable diagnostic tool to determine the extent of tumour disease and for planning surgical treatment (Bakker et al, 1991; Ahlman et al, 1994) .
Five different subtypes of human somatostatin receptors (sstr) have been cloned and functionally characterized. Each receptor is encoded by a unique gene, located on separate chromosomes in man . The somatostatin receptors belong to the superfamily of G-protein-coupled receptors with seven putative membrane-spanning domains. The physiological or pathophysiological roles of each receptor subtype have been difficult to establish because of the lack of subtype-specific receptor agonists or antagonists. However, the pharmacology of the cloned somatostatin receptor subtypes have been studied in expression systems using non-neuroendocrine cells, demonstrating preferential binding of octreotide tor sstr2 and 5 Patel and Srikant, 1994) . Based on binding studies of the cloned receptors, sstr2 has been suggested to be the main target for octreotide and a prerequisite for tumour imaging. This assumption has been supported by studies comparing octreotide scintigraphy with the expression of sstr subtypes in gastroenteropancreatic endocrine tumours (Kubota et al, 1994; John et al, 1996) . However, in these studies only small numbers of each tumour type were analysed by reverse transcriptase polymerase chain reaction (RT-PCR) and correlated with octreotide scintigraphy or somatostatin autoradiography.
In the present study, we have for the first time examined the expression of sstr subtypes in a series of gastrointestinal carcinoids using subtype-specific riboprobes and high-stringency Northern analysis. The results were compared with the findings obtained at ["'In] DTPA-D-Phe'-octreotide scintigraphy. Furthermore, we studied the secretory responses of individual tumours to octreotide in primary tumour cell cultures and in the clinical situation. 
Northern analysis
Tumour biopsies obtained at surgery were immediately frozen in liquid nitrogen and stored at -80°C until extraction of RNA. Total RNA was prepared by acid guanidinum thiocyanate-phenolchloroform extraction (Chomczynski and Sacchi, 1987) . Samples of RNA (20 ig per sample) were heat denatured and electrophoresed in a 1% agarose gel with 2.2 M formaldehyde, 1 mM EDTA, 5 mM sodium acetate and 20 mm MOPS (pH 7.0) as running buffer. RNA was transferred to positively charged nylon membranes (Boehringer Mannheim, Mannheim, Germany) using a vacuum transfer system and cross-linked to membranes using UV light (Stratalinker, Stratagene, La Jolla, CA, USA). Membranes were hybridized in rotating flasks at 65°C. Prehybridization was carried out for 2-4 h in a solution of 5 x sodium saline citrate (SSC), 50% formamide, 0.1% N-lauroylsavcosine, 0.02% SDS and 5% blocking reagent (Boehringer) followed by hybridization overnight with 32P-labelled antisense RNA probes added to the prehybridization solution. Stringency washing was performed at 65°C using 0.1 x SSC (15 min x 3). 32p_ labelled RNA probes for the five sstr subtypes were generated from linearized plasmids using SP6 or T7 RNA polymerase. Labelled sense RNA probe served as non-specific controls. Specific labelling was detected by 1-4 days' exposure on an imaging plate followed by reading in a PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA). Transcript sizes were estimated using a 0.24-9.5 kb RNA Ladder (Gibco BRL, Gaithersburg, MD, USA). To determine the amount of RNA crosslinked to the membranes, membranes were reprobed with a 1.0-kb human G3PDH cRNA probe (Cat. no. 9805; Clontech, Palo Alto, CA, USA).
Probes sstrl A 1.126-bp fragment of human sstrl (Yamada et al, 1992) corresponding to nucleotides 352-1478 was generated using PCR from genomic DNA and subcloned into a pGEM-T vector (Promega). The identity of the cloned fragment was confirmed by sequencing. cRNA probes were generated from plasmids linearized with PstI using T7 RNA polymerase. sstr2 A 1.7-kb BamHI-HindIII fragment of human sstr2 (Yamada et al, 1992) cloned into a pGEM-3Z vector (Promega) was generously supplied by Graeme I Bell, University of Chicago, IL, USA. The identity of the fragment was confirmed by sequencing. cRNA probes were generated from plasmids linearized with BamHI using SP6 RNA polymerase. sstr3 A 1.9-kb Ncol-HindIll fragment of human sstr3 (Yamada et al, 1992) in pCMV6c was generously supplied by Graeme I Bell, University of Chicago, IL, USA. The fragment was subcloned into a pGEM-3Z vector. The identity of the subcloned fragment was confirmed by sequencing. cRNA probes were generated from plasmids linearized with KpnI using SP6 RNA polymerase. sstr4 A 2.0-kb NaeI-XbaI fragment of human sstr4 cloned into pBluescript II SK+ was generously supplied by Friedrich Raulf, Preclinical Research, Sandoz, Basle, Switzerland. The identity of the fragment was confirmed by sequencing. cRNA probes were generated from plasmids linearized with XbaI using T7 RNA polymerase. sstr5 A 1.6-kb EcoRI-SalIl fragment of human sstr5 (Yamada et al, 1993) cloned into pCMV6c was generously supplied by Susumo Seino, Chiba University School of Medicine, Japan. The fragment was subcloned into a pGEM-3Z vector. The identity of the subcloned fragment was confirmed by sequencing. cRNA probes were generated from plasmids linearized with EcoRI using SP6 RNA polymerase.
Cell cultures
Primary cultures from six carcinoid tumours were prepared as described previously (Ahlman et al, 1988 
Statistical methods
For statistical analysis of tissue culture experiments unpaired t-test (two-tailed) was used. Values are given as means ± s.e.m.
RESULTS

Somatostatin receptor scintigraphy and T/B 1111n activity concentration ratios
All patients (n = 12) had positive tumour imaging with octreotide scintigraphy at the site of biopsy. I"I In activity concentrations were determined in the primary tumour and metastases of two midgut carcinoids (cases 1 and 7) and of one foregut carcinoid (case 10). The T/B ratios were very high in the tumour tissues ranging from 32 to 651 ( (Figure 1 ). The hybridization signal estimated by densitometry was much higher for sstr4 and sstr5 (10-to 100-fold) than for sstrl, sstr2 and sstr3 in both midgut and foregut carcinoids. The two thymic carcinoids (cases 11 and 12, (Table 2 ). The effect of octreotide on isolated tumour cells was studied in primary cultures of four midgut carcinoids (cases 1, 2, 5 and 9) and two foregut (thymic) carcinoids (case 11 and 12). Incubation of midgut tumours with octreotide (10 ,UM) for 7-12 days significantly reduced the spontaneous secretion of 5-HT and 5-HIAA from tumour cells by 45-71% and 41-94% respectively (Table 3) . Incubation of thymic carcinoid tumours with octreotide (10 gM) for 8 days failed to reduce the secretion of 5-HT to any significant degree, whereas the secretion of 5-HIAA was reduced by 21%. Octreotide treatment of BON cells for 4 days increased the secretion of 5-HT by 27% but reduced the secretion of 5-HIAA by 54%. Figure ratios in carcinoid tumours compared with other neuroendocrine tumours, for example medullary thyroid carcinoma (ForssellAronsson et al, 1995; Wangberg et al, 1996; Ahlman et al, 1997; Tisell et al, 1997) . In general, the T/B ratios seemed to be somewhat lower in primary tumours and lymph node metastases than in liver metastases. Northern blot analysis in these patients was performed on metastatic tumour material showing the expression of all receptor subtypes in two tumours and the expression of sstr2, 4 and 5 in one tumour. Nevertheless, liver metastases from the last tumour had the highest T/B ratios and tumour cells also had a marked antisecretory response to octreotide. These findings further indicate that "'IIn-labelled octreotide can be used for radiation therapy of disseminated carcinoid disease provided that "'In is internalized into the tumour cells, as recently demonstrated (Andersson et al, 1997) . Phase I radiation therapy studies on patients with disseminated neuroendocrine tumours have demonstrated effects of "'In-labelled octreotide on hormonal symptoms and biochemical markers as well as on tumour size Krenning et al, 1996) . For the first time, we have examined the expression of somatostatin receptor subtypes in a series of human carcinoid tumours by Northern analysis and subtype-specific riboprobes. This analysis combines high sensitivity and specificity and allows semiquantitative estimation of receptor expression. Using this method, all five somatostatin receptor subtypes could be demonstrated in a majority of carcinoid tumours, both of foregut and of midgut origin, although the strongest hybridization signals were observed for sstr4 and 5. Our data confirm the expression of sstr2 in all scintigraphically positive carcinoid tumours except for one tumour. In addition, expression of multiple somatostatin receptor subtypes including a high expression of sstr4 and sstr5 was demonstrated in carcinoid tumours. This is at a variance with previous studies, in which only sstr2 could be regularly demonstrated by RT-PCR in scintigraphically positive neuroendocrine tumours (John et al, 1996) . One, less likely, explanation for this discrepancy is the difference in methods used to demonstrate sstr subtypes. Another, more likely, explanation for the different results is differences in the tumour material studied. In the present study, we have primarily investigated a group of metastasizing ileal carcinoids that express all five sstr subtypes. Other endocrine tumours, including foregut carcinoids, medullary and papillary thyroid carcinoma have a different pattern of sstr expression as determined by Northern blotting, often lacking one or several sstr subtypes Tisell et al, 1997) . In view of these findings and the pharmacological profile of octreotide, one may assume that both sstr2 and sstr5 are responsible for the positive tumour imaging and high "'IIn activity concentrations observed in carcinoid tumours using octreotide scintigraphy.
The secretory response of carcinoid tumours to somatostatin receptor stimulation was studied both in the clinical situation and in cultured tumour cells. Patients treated with octreotide responded with marked reduction of hormonal symptoms as well as reduction of tumour markers (urinary 5-HIAA excretion), which indicates an inhibitory effect of somatostatin receptors on secretory processes in carcinoid tumours. In vitro experiments on cultured tumour cells confirmed that octreotide exerts a direct inhibitory effect on hormone secretion from carcinoid tumour cells. Both 5-HT and 5-HIAA concentrations in culture media were significantly reduced, suggesting a decrease in both hormone synthesis, secretion and metabolism after octreotide treatment. Under the experimental conditions studied octreotide does not appear to have an antiproliferative effect on tumour cells (Wangberg et al, 199 1; Nilsson et al, 1992) . The reduction of 5-HT and 5-HIAA levels observed after octreotide thus appears to be a highly specific effect of somatostatin receptor activation. The exact mechanisms by which octreotide inhibits hormone secretion in carcinoid tumours is not known, but it is noteworthy that octreotide was more effective in reducing hormone secretion from midgut carcinoids than from foregut carcinoids, despite a similar expression of somatostatin receptor subtypes. This difference in response to octreotide may reflect different absolute or relative expression of somatostatin receptor subtypes in tumours, but may also be due to different mechanisms for receptor coupling and intracellular messenger systems. Further studies, using subtypespecific agonists or antagonists, are necessary to elucidate the exact role of each somatostatin receptor subtype in the control of hormone secretion and growth of carcinoid tumours.
